Nektar reports updated response data for immuno-oncology combo

Nektar Therapeutics (NASDAQ:NKTR) reported response data from 60 evaluable patients with solid tumors who were naïve to immunotherapy in the Phase Ib/II PIVOT-02 trial evaluating the company's NKTR-214 plus anti-PD-1 mAb Opdivo nivolumab. The data were released in an abstract ahead of the American Society of Clinical Oncology meeting in Chicago.